18402154. SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE simplified abstract (Duke University)
Contents
SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE
Organization Name
Inventor(s)
Jennifer Freedman of Durham NC (US)
Steven Patierno of Durham NC (US)
Daniel George of Durham NC (US)
Bruce Sullenger of Durham NC (US)
Bonnie Lacroix of Durham NC (US)
Brendon Patierno of Durham NC (US)
SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE - A simplified explanation of the abstract
This abstract first appeared for US patent application 18402154 titled 'SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE
The present disclosure involves methods and compositions for treating cancer, specifically castrate-resistant prostate cancer, by using splice-switching oligonucleotides to downregulate AR expression.
- Splice-switching oligonucleotides are utilized to target and reduce AR expression in cancer cells.
- The methods described in the patent application focus on treating castrate-resistant prostate cancer.
- The innovation aims to provide a more targeted and effective treatment for this specific type of cancer.
- By downregulating AR expression, the splice-switching oligonucleotides may help inhibit cancer cell growth and proliferation.
- This technology offers a potential new approach to managing and treating castrate-resistant prostate cancer.
Potential Applications: - Treatment of castrate-resistant prostate cancer - Development of targeted cancer therapies - Research in the field of oncology and molecular biology
Problems Solved: - Lack of effective treatments for castrate-resistant prostate cancer - Need for more targeted and specific cancer therapies - Challenges in inhibiting cancer cell growth and proliferation
Benefits: - Improved treatment outcomes for patients with castrate-resistant prostate cancer - Potential for personalized medicine approaches in cancer treatment - Enhanced understanding of molecular mechanisms in cancer progression
Commercial Applications: Title: Innovative Cancer Treatment Technology for Castrate-Resistant Prostate Cancer Description: This technology has the potential for commercialization in the pharmaceutical industry for developing targeted cancer therapies. It could also be used in research institutions for studying cancer biology and developing new treatment strategies.
Questions about Cancer Treatment Technology: 1. How do splice-switching oligonucleotides work to downregulate AR expression in cancer cells? 2. What are the potential implications of this technology for the future of cancer treatment?
Frequently Updated Research: Ongoing studies and clinical trials related to splice-switching oligonucleotides and their efficacy in treating castrate-resistant prostate cancer are continuously evolving. Stay updated on the latest research findings in this field to understand the advancements in cancer treatment.
Original Abstract Submitted
The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.
